JonathanIanSilverbergMD
Dermatology • Washington, DCAssociate Professor of Dermatology, George Washington University School of Medicine and Health Sciences
Dr. Silverberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2150
Ste 2B-430
Washington, DC 20037- Is this information wrong?
Summary
- Dr. Jonathan Silverberg is a dermatologist in Washington, DC and is affiliated with George Washington University School of Medicine and Health Sciences. He received his medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice 8 years. He is experienced in general dermatology, atopic dermatitis, contact dermatitis, allergic contact dermatitis, and eczema.
Education & Training
Icahn School of Medicine at Mount SinaiResidency, Dermatology, 2010 - 2013
SUNY Health Science Center at BrooklynInternship, Internal Medicine, 2009 - 2010
State University of New York Downstate Medical Center College of MedicineClass of 2009
Certifications & Licensure
OR State Medical License 2012 - Present
DC State Medical License 2019 - 2024
MD State Medical License 2019 - 2021
IL State Medical License 2013 - 2020
NY State Medical License 2012 - 2014- American Board of Dermatology Dermatology
Publications & Presentations
PubMed
- Targeting the aryl hydrocarbon receptor as a strategy to expand the therapeutic armamentarium in atopic dermatitis.Eichenfield, L., Silverberg, J., Hebert, A., Boguniewicz, M.> ;The Journal of Dermatological Treatment. 2024 Dec 1
- Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Sev...Marjolein de Bruin-Weller, H Chih-Ho Hong, Delphine Staumont-Sallé, Kilian Eyerich, Melinda Gooderham, Mona Shahriari, Lotus Mallbris, Amber Reck Atwater, Maria Jose R...> ;Dermatology and Therapy. 2024 May 3
- Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).Eric L Simpson, Vimal H Prajapati, Yael A Leshem, Raj Chovatiya, Marjolein S de Bruin-Weller, Sonja Ständer, Andrew E Pink, Brian M Calimlim, Wan-Ju Lee, Henrique Teix...> ;Dermatology and Therapy. 2024 May 2
- Join now to see all
Journal Articles
- Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic DermatitisJonathan I Silverberg, Eric L Simpson, Hernan Valdez, JAMA Dermatology
- Dupilumab Provides Important Clinical Benefits to Patients with Atopic Dermatitis Who Do Not Achieve Clear or Almost Clear Skin According to the Investigator's Global ...J I Silverberg, The British Journal of Dermatology
- Inpatient Burden of Juvenile Dermatomyositis Among Children in the United StatesMichael C Kwa, Jonathan I Silverberg, BioMed Central
- Join now to see all
Authored Content
- Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic DermatitisJune 2020
Press Mentions
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (Tapinarof) Cream, 1% in Adults and Children as Young as 2 Years OldMay 16th, 2023- Lebrikizumab Could Soon Be a New Treatment for Atopic DermatitisApril 17th, 2023
- NJEM and BJD Publish Encouraging Results for Almirall’s LebrikizumabApril 3rd, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
